Similar stratification of TCGA_GBM on MGMT promoter methylation status—another well-characterized epigenetic biomarker for glioma chemosensitivity—demonstrated neither significant differential NY-ESO-1 nor CTA expression (Supplementary Fig. S1B; ref. 31). This evidence concerns the gene CTAG1B and central nervous system cancer.